Iron Deficiency Anemia
Hematology
6
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
1
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
UP
Pierre FabreFrance - Aignan
2 programs2
Tardyferon 80 mgPhase 11 trial
V0355Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UCB PharmaFerrous
EisaiH. pylori treatment
Keros TherapeuticsKER-047
Rockwell MedicalTriferic AVNU
Pierre FabreV0355
Pierre FabreTardyferon 80 mg
Clinical Trials (6)
Total enrollment: 379 patients across 6 trials
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects
Start: Mar 2011Est. completion: Nov 2013256 patients
Phase 3Completed
The Effect of H. Pylori Infection on Iron Metabolism
Start: Nov 2002Est. completion: Sep 200739 patients
Phase 2/3Completed
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Start: Nov 2023Est. completion: Jan 20260
Phase 2Withdrawn
Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy
Start: Nov 2021Est. completion: May 2022
Phase 2Unknown
Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia
Start: Aug 2015Est. completion: May 201629 patients
Phase 1Terminated
Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia
Start: Jan 2013Est. completion: Mar 201455 patients
Phase 1Completed
Related Jobs in Hematology
Délégué Médical LLC/Myélome (H/F) - secteurToulouse
Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday
MSL Hematología L - Sur
Johnson & Johnson
Sevilla, Spain
Yesterday
Senior Manager – Strategy & Business Transformation
Johnson & Johnson
Mumbai, India
Yesterday
Sr. Director Marketing
Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr
Key Account Specialist Hematology
Johnson & Johnson
Beirut, Lebanon
4d ago
Hematology Field Medical Director, non-MD
Pfizer
Remote
4d ago
$177K - $294K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space